American biotech giant focused on RNA therapeutics and vaccines
Vaccine trials targeting Lynch syndrome are expanding, with early-stage studies in the UK and US exploring vaccines that train the immune system to intercept cancerous changes before tumors form. The effort includes mRNA-based approaches and off-the-shelf cell therapies, while other screenings and tests continue to evolve in parallel.
A Bundibugyo-strain Ebola outbreak has produced more than 500 confirmed cases across eastern Democratic Republic of Congo and at least 19 confirmed cases in Uganda. WHO has declared a public health emergency of international concern; authorities are scaling up testing, treatment centres and cross-border preparedness while contact tracing and supplies remain insufficient.
Moderna’s mFlusiva has secured an advisory committee vote in favor of approval for adults 50 and older. The decision follows earlier FDA scrutiny and a high-profile dispute over study design, with the committee citing robust efficacy and a solid safety profile.
Moderna has secured FDA approval for mFlusiva in adults 50-64 with full approval and for 65+ with accelerated approval, based on a 40,000-person study showing reduced flu cases vs standard vaccines. Availability is rolling out ahead of fall, with postmarket studies planned to confirm benefits in seniors.